Literature DB >> 26173428

Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review.

Boris Arbit1, Jonathan C Hsu1.   

Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia and predisposes patients to an increased risk of embolic stroke. After nearly 60 years, warfarin is no longer the only effective therapeutic option for patients with AF. Large randomized trials have consistently shown that non-vitamin K oral anticoagulants (NOACs) including dabigatran, rivaroxaban, apixaban, and edoxaban significantly reduce from the risk of intracranial hemorrhage (ICH) compared with warfarin. We provide a focused review regarding the NOACs and ICH in AF patients by summarizing findings of these large clinical trials, mechanisms of lower ICH, reversal strategies with specific agents, and monitoring strategies.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26173428      PMCID： PMC6490851          DOI： 10.1002/clc.22434

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN： 0160-9289            Impact factor:   2.882


  74 in total

Review 1.  Molecular and cellular biology of blood coagulation.

Authors:  B Furie; B C Furie
Journal:  N Engl J Med       Date:  1992-03-19       Impact factor: 91.245

2.  Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.

Authors:  Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; Kent R Bailey; Walter P Abhayaratna; James B Seward; Teresa S M Tsang
Journal:  Circulation       Date:  2006-07-03       Impact factor: 29.690

3.  1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.

Authors:  Donald J P Pinto; Michael J Orwat; Mimi L Quan; Qi Han; Robert A Galemmo; Eugene Amparo; Brian Wells; Christopher Ellis; Ming Y He; Richard S Alexander; Karen A Rossi; Angela Smallwood; Pancras C Wong; Joseph M Luettgen; Alan R Rendina; Robert M Knabb; Lawrence Mersinger; Charles Kettner; Steven Bai; Kan He; Ruth R Wexler; Patrick Y S Lam
Journal:  Bioorg Med Chem Lett       Date:  2006-05-30       Impact factor: 2.823

4.  Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.

Authors:  Carl van Walraven; Robert G Hart; Daniel E Singer; Andreas Laupacis; Stuart Connolly; Palle Petersen; Peter J Koudstaal; Yuchiao Chang; Beppie Hellemons
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

5.  Clinical outcome of patients with venous thromboembolism and recent major bleeding: findings from a prospective registry (RIETE).

Authors:  J A Nieto; A D De Tuesta; P J Marchena; G Tiberio; J A Todoli; A L Samperiz; M Monreal
Journal:  J Thromb Haemost       Date:  2005-04       Impact factor: 5.824

6.  In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.

Authors:  E Perzborn; J Strassburger; A Wilmen; J Pohlmann; S Roehrig; K-H Schlemmer; A Straub
Journal:  J Thromb Haemost       Date:  2005-03       Impact factor: 5.824

7.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Jack Ansell; Jack Hirsh; Leon Poller; Henry Bussey; Alan Jacobson; Elaine Hylek
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

8.  Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.

Authors:  P C Wong; E J Crain; B Xin; R R Wexler; P Y S Lam; D J Pinto; J M Luettgen; R M Knabb
Journal:  J Thromb Haemost       Date:  2008-02-25       Impact factor: 5.824

Review 9.  Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.

Authors:  Volker Laux; Elisabeth Perzborn; Dagmar Kubitza; Frank Misselwitz
Journal:  Semin Thromb Hemost       Date:  2007-07       Impact factor: 4.180

10.  The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dietmar Gansser; Willy Roth
Journal:  Br J Clin Pharmacol       Date:  2007-05-15       Impact factor: 4.335
View more
  1 in total

1.  Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project.

Authors:  Wen-Hua Li; Duo Huang; Chern-En Chiang; Chu-Pak Lau; Hung-Fat Tse; Esther W Chan; Ian C K Wong; Gregory Y H Lip; Pak-Hei Chan; Chung-Wah Siu
Journal:  Clin Cardiol       Date:  2016-11-28       Impact factor: 2.882
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.